A citation-based method for searching scientific literature

Mahip K Verma, Rajan Goel, Nandakumar Krishnadas, Kumar V S Nemmani. Expert Opin Ther Targets 2018
Times Cited: 15







List of co-cited articles
187 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
849
53

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
370
40


GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
234
40

Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.
Jenny Nyberg, Michelle F Anderson, Björn Meister, Ann-Marie Alborn, Anna-Karin Ström, Anke Brederlau, Ann-Christin Illerskog, Ola Nilsson, Timothy J Kieffer, Max Albert Hietala,[...]. J Neurosci 2005
132
40

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
223
33

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
414
33

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
295
33

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
33

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model.
Yanwei Li, WeiZhen Liu, Lin Li, Christian Hölscher. Neuropharmacology 2016
52
33


Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
247
26

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
26

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
481
26


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
351
26

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
339
26

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
166
26


Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
607
26

Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
TracyAnn Perry, Harold W Holloway, Ananda Weerasuriya, Peter R Mouton, Kara Duffy, Julie A Mattison, Nigel H Greig. Exp Neurol 2007
154
20

Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury.
Ian A Tamargo, Miaad Bader, Yazhou Li, Seong-Jin Yu, Yun Wang, Konrad Talbot, Richard D DiMarchi, Chaim G Pick, Nigel H Greig. Exp Neurol 2017
27
20

Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice.
Lital Rachmany, David Tweedie, Yazhou Li, Vardit Rubovitch, Harold W Holloway, Jonathan Miller, Barry J Hoffer, Nigel H Greig, Chaim G Pick. Age (Dordr) 2013
72
20

A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Dong Seok Kim, Ho-Il Choi, Yun Wang, Yu Luo, Barry J Hoffer, Nigel H Greig. Cell Transplant 2017
81
20


Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
175
20

GLP-1 secretion by microglial cells and decreased CNS expression in obesity.
Camilla Kappe, Linda M Tracy, Cesare Patrone, Kerstin Iverfeldt, Åke Sjöholm. J Neuroinflammation 2012
65
20

The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.
Ruben Isacson, Elisabet Nielsen, Karin Dannaeus, Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Lilian Wikström. Eur J Pharmacol 2011
105
20

Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
Yazhou Li, Miaad Bader, Ian Tamargo, Vardit Rubovitch, David Tweedie, Chaim G Pick, Nigel H Greig. J Neurochem 2015
62
20


Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
272
20

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.
Takashi Iwai, Satoshi Ito, Kahori Tanimitsu, Shunichi Udagawa, Jun-Ichiro Oka. Neurosci Res 2006
154
20

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
Dilan Athauda, Thomas Foltynie. Neuropharmacology 2018
56
20

Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.
David Tweedie, Lital Rachmany, Vardit Rubovitch, Yazhou Li, Harold W Holloway, Elin Lehrmann, Yongqing Zhang, Kevin G Becker, Evelyn Perez, Barry J Hoffer,[...]. Alzheimers Dement 2016
43
20

Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
Yazhou Li, David Tweedie, Mark P Mattson, Harold W Holloway, Nigel H Greig. J Neurochem 2010
100
20

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
453
20

Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia.
Shinichiro Teramoto, Nobukazu Miyamoto, Kenji Yatomi, Yasutaka Tanaka, Hidenori Oishi, Hajime Arai, Nobutaka Hattori, Takao Urabe. J Cereb Blood Flow Metab 2011
149
20

Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis.
Yazhou Li, Srinivasulu Chigurupati, Harold W Holloway, Mohamed Mughal, David Tweedie, Daniel A Bruestle, Mark P Mattson, Yun Wang, Brandon K Harvey, Balmiki Ray,[...]. PLoS One 2012
87
20

Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
Jessica Freiherr, Manfred Hallschmid, William H Frey, Yvonne F Brünner, Colin D Chapman, Christian Hölscher, Suzanne Craft, Fernanda G De Felice, Christian Benedict. CNS Drugs 2013
316
20



An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
599
20

Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice.
Mahip K Verma, Rajan Goel, Krishnadas Nandakumar, Kumar V S Nemmani. Eur J Pharmacol 2017
14
21

Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases.
Cláudia P Figueiredo, Fabrício A Pamplona, Tânia L Mazzuco, Aderbal S Aguiar, Roger Walz, Rui Daniel Schröder Prediger. Behav Pharmacol 2010
46
20


TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.
Mychael V Lourenco, Julia R Clarke, Rudimar L Frozza, Theresa R Bomfim, Letícia Forny-Germano, André F Batista, Luciana B Sathler, Jordano Brito-Moreira, Olavo B Amaral, Cesar A Silva,[...]. Cell Metab 2013
262
20

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.
Aileen M Moloney, Rebecca J Griffin, Suzanne Timmons, Rosemary O'Connor, Rivka Ravid, Cora O'Neill. Neurobiol Aging 2010
531
20


Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
Chenhui Ji, Guo-Fang Xue, Guanglai Li, Dongfang Li, Christian Hölscher. Rev Neurosci 2016
38
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.